Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view

J Pharm Pharm Sci. 2007;10(2):321s-337s.

Authors

Vikas Prasad¹, S Fetscher, Richard P Baum

Affiliation

¹ Department of Nuclear Medicine, Center for PET/CT, Zentralklinik Bad Berka, Germany.

PMID: 17718935

No abstract available

Publication types

Review

MeSH terms

Controlled Clinical Trials as Topic
Drug Delivery Systems
Humans
In Vitro Techniques
Neuroendocrine Tumors / drug therapy*
Neuroendocrine Tumors / physiopathology
Nuclear Medicine
Radiopharmaceuticals
Receptors, Peptide / drug effects
Receptors, Peptide / metabolism
Receptors, Somatostatin / drug effects*
Receptors, Somatostatin / metabolism*
Somatostatin / analogs & derivatives
Somatostatin / pharmacology*

Substances

Radiopharmaceuticals
Receptors, Peptide
Receptors, Somatostatin
Somatostatin